Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926614 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
A Phase 4 study of Hepatitis C, sponsored by Brooke Army Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00926614: Completed Phase 4 study of Hepatitis C, sponsored by Brooke Army Medical Center.
NCT00926614 is a Phase 4 study of Hepatitis C that has completed, run by Brooke Army Medical Center. The registered enrollment target is 20 participants, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926614, a Phase 4 study of Hepatitis C, has completed, sponsored by Brooke Army Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.
Conditions Studied
Interventions
- DRUG pioglitazone (Actos)
- DRUG atorvastatin (Lipitor)
Study Locations (1)
Texas
- Brooke Army Medical Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
What the finished NCT00926614 record still lists
NCT00926614 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,890-participant average among 106 other Hepatitis C trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which pioglitazone (Actos) is the first listed.
NCT00926614 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00926614 about?
NCT00926614 is a clinical study titled "Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba". The aim of the study will be to determine if an insulin sensitizing thiazolidinedione plus a lipid lowering agent (statin) improves sustained virologic response rates in patients who have previously not responded or relapsed on standard pegylated interferon and ribavirin therapy.
What is the current status of trial NCT00926614?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2008-09. Estimated completion is 2011-12.
What conditions does trial NCT00926614 study?
This clinical trial studies the following conditions: Hepatitis C.
What interventions are being tested in trial NCT00926614?
The interventions under investigation include: pioglitazone (Actos) (DRUG), atorvastatin (Lipitor) (DRUG).
Who is sponsoring clinical trial NCT00926614?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00926614 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00926614's enrollment target sits among peer trials
20 94th of 106 higher than 9 of 106 other Hepatitis C trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
COMPLETED · Phase 4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
COMPLETED · Phase 4
-
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
COMPLETED · Phase 4
-
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia